Abstract Surgical resection offers the only treatment associated with long-term survival for colorectal cancer (CRC) with hepatic metastasis. Imaging studies are paramount for the identification of potential surgical candidates. Synchronous hepatic disease is identified at presentation in 20-30 % of patients and ultimately, hepatic metastases occur in over 50 % of patients diagnosed with CRC. Computed tomography (CT) has been the imaging standard to identify patients with hepatic metastasis, but the array of preoperative imaging has expanded over the past several years. Currently, ultrasound, CT, magnetic resonance imaging, and positron emission tomography all play a vital role in the management and treatment of stage IV CRC. In addition, patient characteristics such as steatosis and treatment such as neoadjuvant chemotherapy affect imaging of hepatic metastases. The goal of this review is to discuss the current standing of imaging modalities used in the perioperative care of patients with colorectal liver metastasis.
Introduction
Colorectal cancer (CRC) is the second leading cause of cancer-related death in the western world. Following regional lymph node involvement, the liver is the most frequent site of distant metastasis, with 20-30 % of patients presenting with synchronous hepatic metastasis on initial staging [1, 2] . Ultimately, metachronous hepatic metastases occur in over 50 % of patients diagnosed with CRC [3, 4] . Evaluation of these complex patients requires a thorough history and physical examination, laboratory evaluation, and imaging studies. Imaging studies are paramount to preoperative staging and identification of potential surgical candidates. Surgical resection offers the only treatment associated with long-term survival for CRC with hepatic metastasis [5] . In compliance with National Comprehensive Cancer Network Guidelines, computed tomography (CT) has been used as the standard of care to identify patients with hepatic metastasis [6, 7] . Many updates in the field of imaging have occurred in the last 5 years. Currently, ultrasound (US), CT, magnetic resonance imaging (MRI), positron emission tomography (PET), and intraoperative imaging modalities collectively play a vital role in the management and treatment of stage IV CRC. In addition, patient characteristics such as steatosis and treatment options such as neoadjuvant chemotherapy therapy affect imaging of hepatic metastases. The goal of this review is to discuss the current practices in imaging modalities used in the perioperative care of patients with colorectal liver metastasis.
Methods
A systematic review of the literature from January 2003 to July 2013 was performed using the following terms: ''colon neoplasm'' or ''rectal neoplasms;'' and ''liver neoplasms;'' and ''MRI'' or ''MR'' or ''CT'' or ''SCT'' or ''MSCT'' or ''MDCT'' or ''CTAP'' or ''PET'' or ''US'' or ''IOUS'' or ''diagnostic tests''. For each term, the ''explode'' option was used. Additional limits of human subjects and the English language were applied and 466 articles were initially identified.
Reviewers scanned the title, abstract, and key words of the retrieved records and obtained full text of the relevant articles. Reference lists were then searched to identify additional articles. In order to focus on the most current literature, relevant articles from the past 5 years were preferentially selected.
Results

Ultrasound
While traditional US has limited use in preoperative imaging of colorectal hepatic metastasis, several advances in the field of contrast-enhanced US and intraoperative US show promising results.
Traditional US has an advantage of providing very costeffective and widely available imaging (Fig. 1 ). Ultrasound provides a pooled sensitivity and specificity 63.0 and 97.6 % [8 •• ]. While contrast-enhanced US (CEUS) is not available in the United States outside of echocardiography, it deserves mention. Recent prospective studies comparing noncontrast-enhanced US, CT, and MRI to transcutaneous contrast-enhanced US have demonstrated increased sensitivity of contrast-enhanced US to 80.0-91.2 % [9] [10] [11] . This sensitivity range is comparable to multidetector CT (MDCT). Another prospective study that directly compared CEUS to MDCT demonstrated that MDCT had a higher sensitivity for detection of hepatic metastases but this was not statistically significant (89 vs. 80 %; P = 0.06) [12] . While these are promising results and may provide an inexpensive imaging alternative in the future, CEUS in the United States is dependent on Federal Drug Administration approval of the contrast agent. Ultrasound also has the notable weakness of being operator-dependent.
Intraoperative US also warrants brief discussion. Intraoperative US (IOUS) has historically had a significant impact on intraoperative decision-making for the management of CRC with liver metastases. With improved axial imaging, the impact of IOUS has decreased and its performance has been questioned [13, 14] . Despite this, in a recent series of patients who underwent preoperative MDCT, IOUS reported the identification of additional metastases in 16 % and a resultant change in clinical management in 9 % [15 • ]. Contrast-enhanced IOUS has also shown potential with improved sensitivity and specificity compared to traditional IOUS, even in the setting of neoadjuvant therapy [16, 17 •• ] . In one prospective study, consecutive patients underwent preoperative MDCT, IOUS, and contrast-enhanced IOUS. The results indicated that contrast-enhanced IOUS altered the intraoperative decision-making in 20 % of patients. Two lesions that were classified as indeterminate by preoperative MDCT and IOUS were classified as benign, based on contrastenhanced IOUS. Two additional hepatic metastatic CRC lesions were identified by contrast-enhanced IOUS: one lesion that had been classified as indeterminate, and another lesion was not previously identified.
Today, transabdominal US has a very limited role in the evaluation of patients with metastatic colorectal cancer to the liver, but, given time, contrast-enhanced US may play an emerging role. Intraoperative US remains a valuable tool for intraoperative decision-making.
Computed Tomography
Multidetector row computed tomography (MDCT) remains the mainstay for staging colorectal liver metastases (Fig. 2) . MDCT is a reliable tool with pooled sensitivity and specificity of 74.8 and 95.6 %, ranging from 48.4 to 100 and 80 to 100 % (Table 1) 
. When limited to only prospective studies on a per patient basis, sensitivity and specificity are 83.3 and 95.7 %, respectively. As such, CT of the chest, abdomen, and pelvis with IV contrast is the recommended initial imaging modality in staging both colon and rectal cancer by current National Comprehensive Cancer Network (NCCN) guidelines [6, 7] .
Advantages of CT include its easy availability and speed. Disadvantages of CT include the risk of ionizing radiation. While this is a concern, the population of patients with CRC is generally older and less susceptible to the long-term risk associated with ionizing radiation. Contrast agents also have the risk of nephrotoxicity. The greatest limitation of CT is its inability to characterize sub-centimeter lesions.
At this time, MDCT is a convenient and reliable imaging modality that should be used as the imaging staging modality of choice in most patients with the diagnosis of CRC. Special circumstances in which other modalities should be considered include patients with renal impairment or young age and risk of radiation exposure.
Magnetic Resonance Imaging
Over the past 5 years, magnetic resonance imaging (MRI) has evolved. New contrast agents, as well as MRI software and hardware, have resulted in the advancement of this non-invasive imaging. The different modalities, series, and contrast agents may be initially daunting; however, in collaboration with our radiology colleagues, this imaging modality can be more easily understood and applied to our patients. Additional software capabilities also offer three-dimensional reconstructions. MR with Gd-EOB-DTPA, the most common hepatic contrast agent, results in improved sensitivity and specificity for detecting CRC with liver metastasis [19] . Early studies that compared different MR modalities directly, specifically Gadolinium and SPIO, identified no difference in accuracy. When these modalities are compared to CT, both MR techniques provide superior accuracy that is more sensitive for lesions \1 cm in size [20] . As experience with hepatic-specific contrast agents evolves, these agents result in improving lesion identification. A recent prospective study of patients who underwent SPIO MR and Gadobenate (GbD) MR identified 100 % sensitivity in the SPIO group compared to 91 % in the GbD group [21] . Both MR techniques had higher sensitivity when compared to 82 % with CT.
MR
EOB-DTPA improves lesion detection, and DWI assists with lesion characterization. These two modalities in combination result in improved sensitivity and accuracy of small colorectal liver metastases (Fig. 5b) versus either modality independently [22, 23] . These combined imaging modalities ultimately translate into improved detection of CRCLM, specifically for small lesions (\1 cm). While SPIO and Mn-DPDP also improve the sensitivity of MR, these agents are not widely used [24] [25] [26] . Pooled sensitivity and specificity analysis for MR imaging were 81.1 and 97.2 %, ranging from 64.3 to 100 and 90.6 to 98.4 % [8 •• ]. When assessing prospective trials on a per patient basis, the sensitivity and specificity of MR is 88.2 and 92.5 %, respectively. Table 2 demonstrates estimated sensitivities of CT, MR, and MR subgroups.
Magnetic resonance imaging has three advantages over the other imaging modalities discussed. The first advantage is lack of ionizing radiation. A more significant advantage is the recent development and subsequent accuracy of hepatic-specific contrast agents. While these contrast agents continue to have some risk of nephrotoxicity in the form of nephrogenic fibrosis, this entity only occurs in patients with severe baseline renal impairment. The greatest strength of MRI is its ability to characterize subcentimeter lesions, which is a significant drawback in CT imaging modalities. Disadvantages of MRI are four-fold: (1) cost, (2) availability, (3) exam duration, and (4) operator expertise. While none of these obstacles are insurmountable, as healthcare becomes more cost conscious, the use of MR will have to be tailored appropriately.
Currently, MRI should be used in the preoperative evaluation of patients with CRC with known or suspected hepatic metastasis that cannot be completely characterized by other imaging modalities.
Positron Emission Tomography
Positron emission tomography (PET) provides a metabolic map of glucose uptake of the entire body, resulting in identification of metabolic activity in potential lesions. This modality continues to play a major role in the management of patients with stage IV CRC (Fig. 6) . It has an overall sensitivity of 75.9-100 % and specificity of 96.0-100 % in detecting hepatic metastasis [8 •• , 27, 28 • , 29]. The sensitivity of PET declines with decreasing lesion size. For lesions[2 cm, PET/CT has a sensitivity of 100 % [30] . Sensitivity decreases to 54 and 32 % for lesions 1-2 and \1 cm in size, respectively [30] .
PET offers the added benefit of identification of extrahepatic metastasis with reported sensitivities up to 100 % [31] . Compared to CT, PET is superior for the detection of extrahepatic metastases [29, 32] . In a prospective trial, PET sensitivity was equivalent to CT for detection of hepatic metastasis but was superior for extrahepatic sites (63 vs. 25 %) [32] . In this study, PET identified 5 additional patients with extrahepatic disease but also falsely upstaged 3 patients out of a total of 59 [32] . Due to PET's relatively high sensitivity, specificity and ability to identify extrahepatic disease, PET imaging results in clinically significant findings that lead to changes in management in 9-32 % of patients with CRC [31] [32] [33] . PET also plays an important role in the detection of postoperative systemic and local recurrence [29] .
Disadvantages of PET must also be considered. PET/CT results in exposure to ionizing radiation. In addition, the metabolic activity is not specific to metastatic disease and may result in false positive studies.
Currently, routine use of PET is not recommended for diagnosis or staging of clinical stage I-III CRC; however, it is recommended in the following situations:
1. Preoperative assessment of CRC liver metastasis patients prior to surgical resection 2. Determining management if conventional imaging is equivocal for the presence of metastatic disease 3. Determining site of recurrence in the setting of rising CEA when conventional evaluation fails to identify metastatic disease. 
Special Situations
Neoadjuvant Chemotherapy
Patients with untreated hepatic metastases from CRC have a negligible 5-year survival [34] , while patients treated with combination chemotherapy and surgical resection have 5-year survival rates approaching 60 % [5, 35, 36] . With the use of neoadjuvant chemotherapy, the population of patients with CRC and hepatic metastasis eligible for surgery continues to expand [37] . Neoadjuvant regimens including irinotecan and oxliplatin have the most biologic activity but also result in hepatotoxicity [38] [39] [40] . Neoadjuvant therapy results in decreased sensitivity of preoperative imaging for identification of existing colorectal hepatic metastasis [41, 42] . As the use of neoadjuvant therapy expands, preoperative decisions regarding eligible surgical candidates will become more challenging. Accurate detection and localization of all metastatic disease is essential for determining which patients have the potential to undergo a curative R0 resection. Superparamagnetic iron oxide has been shown to be very sensitive for detecting sub-centimeter colorectal hepatic metastases [20] . A recent prospective study evaluating the sensitivity of SPIO-MRI using early contrastenhancing T1 imaging, which results in the creation of isointense liver/vasculature background in which liver metastases stand out, resulted in a detection rate of 77 % in patients receiving neoadjuvant therapy versus 87 % in patients who did not receive chemotherapy [26] . An additional study on SPIO-enhanced MRI following neoadjuvant chemotherapy for hepatic metastasis had a sensitivity of 92 versus 52 % for PET/CT [43] .
MR enhanced with both diffusion-weighted imaging and GD-EOB-DTPA contrast has also shown improved sensitivity in post-neoadjuvant therapy. In a retrospective study of 32 consecutive patients undergoing neoadjuvant chemotherapy with either DWI, GD-EOB-DTPA, or combined DWI and GD-EOB-DTPA MRI performed, the overall sensitivity was 60, 74, and 91 %, respectively, for detecting CRC liver metastasis post-chemotherapy [44 •• ] . The combination of hepatic-specific contrast agents and DWI in MRI has resulted in increased sensitivity and detection of hepatic metastasis post-neoadjuvant therapy for metastatic CRC. Prior to an attempted R0 surgery, the aforementioned modalities should be strongly considered in evaluating high-risk operative candidates who are classified as unresectable on initial CT staging, and those who have shown a significant imaging response on subsequent imaging.
Today, MR in combination with DWI and liver-specific contrast agents provide the most sensitive tool for detecting liver metastasis in CRC patients who have undergone neoadjuvant chemotherapy.
Hepatic Steatosis
Metabolic syndrome and subsequent non-alcoholic liver disease and non-alcoholic steatohepatitis are the most common causes of liver disease in the United States, and their incidence is increasing [45] . Chemotherapy can also result in steatosis of the liver [39, 46] . The ability of noninvasive imaging studies to evaluate steatotic livers continues to evolve [47, 48 • ] . Hepatic steatosis that is secondary to patients' underlying medical comorbidities or due to neoadjuvant chemotherapy results in decreased density of the hepatic parenchyma making the detection of hypovascular colorectal liver metastases more difficult (Fig. 7) . A recent retrospective analysis of 20 consecutive patients with CRC and hepatic metastases who had biopsyproven hepatic steatosis ([25 %) assessed the ability of MDCT and MRI to evaluate hepatic metastasis. MDCT identified 33 (65 %) and MRI identified 45 (88 %) lesions out of the total of 51 lesions identified pathologically [49] . MRI with Gd EOB GDTP was superior to 64 row MDCT scanners in detecting hepatic metastasis in the setting of a steatotic liver [49] . A similar study compared MDCT, MRI, and IOUS and confirmed the finding that MRI was superior to CT in detecting\1 cm CRC hepatic metastases in a steatotic liver (97 vs. 72 %) [50] . The MRI protocol utilized a 3T MRI with Gd-EOB-DTPA, a hepatic-specific contrast agent. The CT was a multidetector 64-row scanner. Intraoperative US identified all lesions but resulted in two false positive lesions that were not confirmed on final Fig. 7 Computed tomography (CT) scan of the same patient as depicted in Fig. 2 after chemotherapy, demonstrating diffuse hepatic steatosis, indicated by lower density of the liver when compared to the pre-treatment image. The metastases are smaller but also much harder to see due to overall decrease in liver density, which is now similar to the density of the metastases. MRI becomes the modality of choice in this scenario, when metastatic margins become harder to measure and new metastases could be missed on CT pathology [50] . The effect of steatosis on echogenicity of colorectal hepatic metastasis on IOUS was also evaluated prospectively in 126 patients [51 •• ] . The majority of CRC with liver metastases were hypoechoic (48 %), followed closely by isoechoic (34 %), while only 18 % were hyperechoic. In steatotic livers, IOUS imaging quality was worse, and CRC with liver metastases were significantly more likely to be hypoechoic, which actually made the lesions more conspicuous [51 •• ] . While MRI is superior to other preoperative imaging modalities identifying CRC with liver metastases in fatty livers, IOUS continues to perform well.
In the setting of hepatic steatosis, MR with hepaticspecific contrast agents is superior to MDCT in detecting CRC with liver metastases. Intraoperative US imaging quality is diminished; however, it still allows for visualization of pertinent lesions and IOUS remains an important adjunct for intraoperative decision-making.
Conclusions
Hepatic metastectomy offers the only treatment associated with long-term survival for CRC with hepatic metastasis. Unfortunately, hepatic metastases occur in over 50 % of patients diagnosed with CRC, and the majority of these patients present with unresectable disease. Imaging studies are paramount not only for identification of hepatic metastasis but also for characterization of these lesions to identify potential surgical candidates. Today, intraoperative US remains a valuable tool for intraoperative decisionmaking. Contrast-enhanced US may play an emerging role in the future. Computed tomography is a convenient reliable imaging modality that is the staging modality of choice in most patients with the diagnosis of CRC. Magnetic resonance imaging technology has had significant advancement and should be used in the preoperative evaluation of patients with CRC with known or suspected hepatic metastasis that cannot be completely characterized by other imaging modalities. The greatest advantage of MRI includes identification and characterization of small lesions. In addition, it provides the greatest accuracy in patients who have received neoadjuvant chemotherapy or in those with hepatic steatosis. While routine use of PET is not recommended for diagnosis or staging in early stage CRC, it is recommended in the preoperative assessment of CRC liver metastasis prior to surgical resection. Innovations in preoperative imaging continue to evolve, resulting in improved identification and characterization of CRC hepatic metastasis. The use of MRI and the recent attendant liver contrast-enhanced agents will allow for more appropriate patient selection for surgical resection with the goal of long-term survival with liver resection.
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